South Korean biopharmaceutical giant Celltrion said Tuesday it posted record earnings in the third quarter, largely buoyed by upbeat sales of biosimilar products and solid contract manufacturing orders.

Celltrion's revenue in the July-September period climbed 4.1 percent on-year to 672.3 billion won ($514 million). Operating profit also went up by 25.2 percent to 267.6 billion won during the same period, while the operating margin came to 39.8 percent.

Celltrion said sales of the company’s main biosimilar products contributed to the improved performance, continuing their upward trend in securing greater shares in key markets, especially in the US and Europe.

According to IQVIA, a drug market research company, Celltrion’s Remsima, a biosimilar drug used to treat autoimmune diseases, and its subcutaneous injection formulation, Remsima SC, held a combined 69.8 percent share in the five major infliximab markets in Europe, including Germany, the UK, France, Italy and Spain, in the second quarter.

The market shares of Celltrion's rituximab Truxima and breast cancer treatment biosimilar Herzuma hit 22.3 percent and 21.7 percent in Europe, respectively.

In the US, however, market shares of Remsima and Truxima both fell slightly to 29.9 percent in the second quarter, from 30.2 percent and 30.5 percent, respectively, in the previous quarter.

Celltrion said some 60 billion won in sales from its drug substance supply deal with Teva Pharmaceutical Industries also made a major contribution to the company’s record high performance in the third quarter.

In August 2022, Celltrion signed a 110-billion-won contract manufacturing deal with Israel-based generic drugmaker Teva Pharmaceutical Industries to supply drug substance for the latter’s Ajovy, a prescription medicine used for the preventive treatment of migraine in adults.

Celltrion also has predicted a positive outlook as the company expects to launch Remsima SC, or Zymfentra, in the US in 2024. The company currently expects annual sales of Zymfentra in the US to reach 600 billion won and grow to 3 trillion won by 2030.

The launch of Zymfentra will also help Celltrion to achieve its sales target of 12 trillion won by 2030.

“After Celltrion completes its merger with Celltrion Healthcare within the year, the integrated Celltrion will be able to take a step forward to its 12-trillion-won sales target by 2030,” an official from Celltrion said.

• ·[New in Korean] Bae Myung
• ·[Today’s K
• ·한·사우디 43년 만의 공동성명 “방산·네옴시티 협력 강화”
• ·[From the Scene] Don't remember Itaewon alley as place of death, victims' families say
• ·Govt. posthumously confers state medal on late Ven. Jaseung
• ·[From the Scene] Don't remember Itaewon alley as place of death, victims' families say
• ·Maestro Semyon Bychkov breaks silence on Israel–Hamas war
• ·정청래, 가결파 징계에 "신상필벌은 당연…잠시 미뤄둔 것"
• ·Ilyon Woo's nonfiction lands on NYT's 10 best books of 2023
• ·Rich culture of masks in Korea, Japan and China on show at Folk Museum
• ·Man fined for assaulting soldiers who refused to praise Kim Jong
• ·국회서 피켓‧고성 사라지나…여야, 정쟁자제 '신사협정' 체결
• ·Merger of Korean OTT platforms Tving and Wavve imminent: sources
• ·N. Korea to close its embassy in Uganda: report
• ·4 North Koreans cross maritime border, say want to defect
• ·Man fined for assaulting soldiers who refused to praise Kim Jong